The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-11-11
DOI
10.3389/fphar.2022.1045235
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19? – Targeting hyperinflammation
- (2022) Afnan Alshnbari et al. CURRENT MEDICAL RESEARCH AND OPINION
- Combined sodium glucose co‐transporter‐2 inhibitor and angiotensin‐converting enzyme inhibition upregulates the renin‐angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double‐blind, placebo‐controlled exploratory trial
- (2022) Marlies Antlanger et al. DIABETES OBESITY & METABOLISM
- Inflammation in obesity, diabetes, and related disorders
- (2022) Theresa V. Rohm et al. IMMUNITY
- Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes
- (2022) Zirui Hao et al. BMC Endocrine Disorders
- The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)
- (2022) Massar Omar et al. Cardiovascular Diabetology
- Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry
- (2022) Pasquale Paolisso et al. Cardiovascular Diabetology
- Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
- (2022) Kieran F. Docherty et al. CIRCULATION
- Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes
- (2022) Raffaele Marfella et al. PHARMACOLOGICAL RESEARCH
- Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure
- (2022) Kentaro Ejiri et al. Scientific Reports
- Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials
- (2022) Lucia Scisciola et al. Frontiers in Cardiovascular Medicine
- Plasminogen activator inhibitor-1 reduces cardiac fibrosis and promotes M2 macrophage polarization in inflammatory cardiomyopathy
- (2021) Christian Baumeier et al. BASIC RESEARCH IN CARDIOLOGY
- Adiponectin, Leptin and Cardiovascular Disorders
- (2021) Shangang Zhao et al. CIRCULATION RESEARCH
- Role of Oxidative Stress and Severity of Diabetic Retinopathy in Type 1 & Type 2 Diabetes
- (2021) Kholoud Albokhary et al. OPHTHALMIC RESEARCH
- Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58
- (2021) Avivit Cahn et al. DIABETES CARE
- Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo‐controlled, exploratory study
- (2021) Jonas Oldgren et al. DIABETES OBESITY & METABOLISM
- Leptin in Leanness and Obesity
- (2021) Nikolaos Perakakis et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Combined Associations of Serum Ferritin and Body Size Phenotypes With Cardiovascular Risk Profiles: A Chinese Population-Based Study
- (2021) Bowen Zhou et al. Frontiers in Public Health
- Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
- (2021) Andrei C. Sposito et al. Cardiovascular Diabetology
- Glucagon‐like peptide‐1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomised controlled trials
- (2021) Jonathan J. H. Bray et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibitors as calorie restriction-mimetics: insights on longevity pathways and age-related diseases
- (2021) Caroline W S Hoong et al. ENDOCRINOLOGY
- PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target
- (2021) Rawan Altalhi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Adipokines and Subclinical Cardiovascular Disease in Post‐Menopausal Women: Study of Women's Health Across the Nation
- (2021) Susan A. Everson‐Rose et al. Journal of the American Heart Association
- Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo‐controlled study
- (2021) Kirsten Thiele et al. DIABETES OBESITY & METABOLISM
- The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non‐alcoholic fatty liver disease
- (2021) Susrichit Phrueksotsai et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Does daily fasting shielding kidney on hyperglycemia-related inflammatory cytokine via TNF-α, NLRP3, TGF-β1 and VCAM-1 mRNA expression
- (2021) Arzu Bilen et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
- (2021) Agata Winiarska et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Comparison of the effects of three kinds of glucose‐lowering drugs on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open‐label, three‐arm, active control study
- (2020) Tomoe Kinoshita et al. Journal of Diabetes Investigation
- Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study
- (2020) Naoto Katakami et al. Cardiovascular Diabetology
- Mechanisms of Sodium–Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics
- (2020) Ele Ferrannini et al. DIABETES CARE
- A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress
- (2020) Jonathan J.H. Bray et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial
- (2020) Alexander J M Brown et al. EUROPEAN HEART JOURNAL
- Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria – A double blind randomized placebo-controlled crossover trial
- (2020) Mie K. Eickhoff et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis
- (2020) Shintaro Sakurai et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
- (2020) Milton Packer et al. CIRCULATION
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
- (2020) Faiez Zannad et al. LANCET
- Attenuation of weight loss through improved antilipolytic effect in adipose tissue via the SGLT2 inhibitor tofogliflozin
- (2019) Akihiro Yoshida et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease
- (2019) Yoshimasa Aso et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
- (2019) Aino Latva-Rasku et al. DIABETES CARE
- How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
- (2019) Agnes Bosch et al. Cardiovascular Diabetology
- Effects of Dapagliflozin vs. Vildagliptin on Cardiometabolic Parameters in Diabetic Patients with Coronary Artery Disease: A Randomised Study
- (2019) A. Phrommintikul et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study)
- (2019) Masaya Koshizaka et al. DIABETES OBESITY & METABOLISM
- Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections
- (2019) Chintan V. Dave et al. ANNALS OF INTERNAL MEDICINE
- Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
- (2019) Sabine Kahl et al. DIABETES CARE
- Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes
- (2019) Peili Wu et al. HORMONE AND METABOLIC RESEARCH
- Diabetes, heart failure, and renal dysfunction: The vicious circles
- (2019) Eugene Braunwald PROGRESS IN CARDIOVASCULAR DISEASES
- Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet
- (2019) Liang Xu et al. BMJ Open Diabetes Research & Care
- SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials
- (2018) Robert Puckrin et al. ACTA DIABETOLOGICA
- The effect of dapagliflozin treatment on epicardial adipose tissue volume
- (2018) Takao Sato et al. Cardiovascular Diabetology
- Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period
- (2018) Yutaka Seino et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers
- (2018) Claire C. J. Dekkers et al. DIABETES OBESITY & METABOLISM
- Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes
- (2018) W. Timothy Garvey et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance
- (2018) Sachiko Hattori Diabetology & Metabolic Syndrome
- Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
- (2017) Yan Zheng et al. Nature Reviews Endocrinology
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
- (2017) Liang Xu et al. EBioMedicine
- Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials
- (2016) Dandan Li et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study
- (2016) Hisamitsu Ishihara et al. DIABETES OBESITY & METABOLISM
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
- (2016) Jason H Y Wu et al. Lancet Diabetes & Endocrinology
- IL-6 in diabetes and cardiovascular complications
- (2014) Dan Qu et al. BRITISH JOURNAL OF PHARMACOLOGY
- Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study
- (2014) Kohei Kaku et al. Cardiovascular Diabetology
- Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range
- (2012) C. J. Bailey et al. DIABETES OBESITY & METABOLISM
- The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases
- (2009) Hunjoo Ha et al. Nature Reviews Nephrology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search